Xilio Development Inc Total Liabilities
Xilio Development Inc total liabilities. Based on the latest financial reports, Xilio Development Inc (XLO) has total liabilities worth $81.99 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Xilio Development Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Xilio Development Inc (2019–2025)
Total liabilities of Xilio Development Inc from 2019 to 2025. This chart illustrates how Xilio Development Inc's total liabilities have evolved over time, based on quarterly financial data.
Xilio Development Inc Competitors by Total Liabilities
The table below lists competitors of Xilio Development Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Katmerciler Arac Ustu Ekipman Sanayi ve Ticaret AS
IS:KATMR
|
Turkey | TL4.66 Billion |
|
Making Science Group S.A.
MC:MAKS
|
Spain | €138.80 Million |
|
S.Y.PANEL Co Ltd
KQ:109610
|
Korea | ₩301.28 Billion |
|
Me2on Co. Ltd
KQ:201490
|
Korea | ₩25.86 Billion |
|
Whitbread PLC
LSE:WTB
|
UK | GBX6.43 Billion |
|
China Fineblanking Technology Co Ltd
TWO:1586
|
Taiwan | NT$1.87 Billion |
|
Ginar Technology Co Ltd
TWO:6151
|
Taiwan | NT$569.81 Million |
|
News Network Corporation Public Company Limited
BK:NEWS
|
Thailand | ฿1.00 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Xilio Development Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see XLO current and non-current assets.
Liquidity & Leverage Metrics
Xilio Development Inc Total Liabilities Ratios Explained
Xilio Development Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xilio Development Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xilio Development Inc (2019–2025)
The table below shows the annual total liabilities of Xilio Development Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $119.41 Million | +123.30% |
| 2024-12-31 | $53.48 Million | +121.91% |
| 2023-12-31 | $24.10 Million | -28.10% |
| 2022-12-31 | $33.52 Million | -7.33% |
| 2021-12-31 | $36.17 Million | -13.06% |
| 2020-12-31 | $41.60 Million | +71.82% |
| 2019-12-31 | $24.21 Million | -- |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumo… Read more